However, similar to non-diabetic patients, ruxolitinib significantly decreased mROS levels in HSVSMCs from T2DM patients with or without IL-6/sIL-6Rα versus untreated control cells (p < 0.05, n = 6; Figure 2D). The gene discussed is IL6; the disease is type 2 diabetes mellitus.